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Nucleotide monophosphate kinases (NMPKs) are potential antimicrobial drug
targets owing to their role in supplying DNA and RNA precursors. The present
work reports the crystal structure of Staphylococcus aureus guanylate
monophosphate kinase (SaGMK) at 1.9 A˚ resolution. The structure shows that
unlike most GMKs SaGMK is dimeric, confirming the role of the extended
C-terminus in dimer formation as first observed for Escherichia coli GMK
(EcGMK). One of the two SaGMK dimers within the crystal asymmetric unit
has two monomers in different conformations: an open form with a bound
sulfate ion (mimicking the -phosphate of ATP) and a closed form with bound
GMP and sulfate ion. GMP-induced domain movements in SaGMK can thus be
defined by comparison of these conformational states. Like other GMKs, the
binding of GMP firstly triggers a partial closure of the enzyme, diminishing the
distance between the GMP-binding and ATP-binding sites. In addition, the
closed structure shows the presence of a potassium ion in contact with the
guanine ring of GMP. The potassium ion appears to form an integral part of the
GMP-binding site, as the Tyr36 side chain has significantly moved to form a
metal ion–ligand coordination involving the lone pair of the side-chain O atom.
The potassium-binding site might also be exploited in the design of novel
inhibitors.
1. Introduction
Staphylococcus aureus is one of the most common causes of noso-
comial infections found in intensive-care units (McGahee & Lowy,
2000). The ability of S. aureus to colonize and infect almost any tissue
makes it responsible for a broad range of human diseases (Lowy,
1998). Many such infections can give rise to life-threatening condi-
tions including bacteraemia, endocarditis, sepsis or toxic shock
syndrome (Lowy, 1998). Worryingly, the emergence of methicillin-
resistant S. aureus (MRSA) strains makes the treatment of infections
arising from this pathogen increasingly difficult. Multidrug-resistant
MRSA has become common in developed countries (Fluit et al.,
2001), requiring treatment by vancomycin. Unfortunately, vanco-
mycin-resistant strains have also been reported (Hiramatsu, 2001).
New and well chosen drug targets are thus necessary in order to
develop novel antibacterials to overcome the current problems
associated with the treatment of MRSA.
One such potential target for novel antibacterial drugs is S. aureus
guanylate monophosphate kinase (SaGMK; EC 2.7.4.8), the structure
of which we describe in this report. SaGMK is a 24 kDa protein which
belongs to the nucleoside monophosphate kinase (NMPK) super-
family and catalyses reversible phosphoryl transfer from a nucleotide
donor to a nucleotide acceptor. GMKs are responsible for phos-
phorylation of (d)GMP to (d)GDP using ATP as phosphoryl donor
(Agarwal et al., 1978). GMKs are involved in the synthesis of
nucleotide precursors, indirectly modulating the synthesis of DNA
and RNA; thus, inhibition of SaGMK would affect bacterial growth.
Additional roles of GMKs that may have potential in other ther-
apeutic areas derive from their involvement in the recycling of cGMP
(Hall & Kuhn, 1986) as well as in the activation of some guanosine-
analogue prodrugs used to treat certain cancers and viral infections
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(Miller et al., 1992). Recently, the structure of Escherichia coli
guanylate kinase in complex with the monophosphate of the anti-
herpes drug ganciclovir has been reported (Hible, Daalova et al.,
2006).
Like most NMPKs, GMKs consist of three domains: the core, the
lid and the NMP-binding domains (Yan & Tsai, 1999). The core
domain consists of a four-stranded -sheet flanked by -helices and
also contains the P-loop which binds the ATP -phosphate. The lid
domain forms interactions with ATP when the protein is in the closed
conformation. GMKs and other NMPKs are known to undergo
conformational changes from an open and unbound form to a closed
conformation bound to one ligand and then to a fully closed
conformation bound to both ligands (Sekulic et al., 2002; Kotaka et
al., 2006; Vonrhein et al., 1995). The closure of the lid and the NMP-
binding domain onto the core domain allows the assembly of the
catalytic machinery and the formation of an associative transition
state (Yan & Tsai, 1999).
To date, GMK crystal structures from E. coli (Hible et al., 2005),
Mycobacterium tuberculosis (Hible, Christova et al., 2006), Sacchar-
omyces cerevisiae (Stehle & Schulz, 1992) and mouse (Sekulic et al.,
2002) have been solved. We report here the structures of unliganded
SaGMK and SaGMK complexed with GMP at 1.9 A˚ resolution.
2. Materials and methods
2.1. Protein purification
The S. aureus GMK-encoding DNA sequence was PCR-amplified
using the following primers: GTCGTAACATATGGATAATG and
GTGGATCCAACATTATTTTTTAG. The PCR product was sub-
cloned into the E. coli expression vector pET15b using NdeI and
BamHI restriction sites to yield the recombinant plasmid pMUT67.
The E. coli expression strain Codon+, transformed with pMUT67, was
grown in an orbital incubator at 303 K in LB medium supplemented
with 100 mg ml1 ampicillin and 35 mg ml1 chloramphenicol until an
attenuance at 550 nm of 0.6 was reached. IPTG was then added to a
final concentration of 0.2 mg ml1 and the culture was incubated for a
further 5 h at 303 K. Cells were then harvested by centrifugation and
the pellet was resuspended in buffer A (50 mM potassium phosphate
pH 7.2, 1 mMDTT) and 1 mM benzamidine. The cells were disrupted
by sonication and centrifuged at 10 000g for 42 min. The cell-free
supernatant was applied onto an IMAC column (9  5 cm) charged
to one-third capacity with Zn2+ and pre-equilibrated with buffer A.
The column was eluted with a linear 0.0–0.3M imidazole gradient in
buffer A and SaGMK-containing fractions (identified by SDS–
PAGE) were pooled, dialysed against buffer A and loaded onto a
hydroxyapatite column (9  5 cm) pre-equilibrated with buffer A.
SaGMKwas eluted with a 1 l linear gradient of 50–400 mM potassium
phosphate buffer pH 7.2 containing 1 mM DTT. On average, the
purification protocol produced 400 mg pure protein from 25 g cell
paste. Finally, SaGMK was buffer-exchanged into 20 mM Tris pH 7.2,
40 mM KCl and 0.1% azide and then concentrated to 18 mg ml1.
2.2. Crystallization and data collection
GMP (5 mM) and ATPS (5 mM) were added to SaGMK for
initial screening of 768 crystallization conditions, including those
from Hampton Research, Wizard and Emerald kits. A Cartesian
Technologies pipetting robot was used to set up 100 + 100 nl sitting
drops in Greiner 96-well plates, which were placed in a TAP storage
vault equipped with an automated imaging system at the Oxford
Protein Production Facility (Walter et al., 2005). After optimization,
crystals grew in 20% PEG 3350, 0.2M LiSO4 and 0.1M Tris–HCl
pH 8.
X-ray diffraction data were collected at the ESRF ID14.1 beamline
from a crystal cryoprotected by the addition of 20% ethylene glycol.
Images were indexed and integrated with DENZO and data were
merged using SCALEPACK (Otwinowski &Minor, 1996). The space
group was P21 and the unit-cell parameters were a = 70.0, b = 93.9,
c = 83.9 A˚,  = 110.6, with four monomers in the asymmetric unit.
Detailed statistics for X-ray data collection and refinement are given
in Table 1. The structure was solved using the automated molecular-
replacement program MrBUMP (Keegan & Winn, 2006) with the
coordinates of E. coli guanylate kinase (PDB code 2anb; Hible et al.,
2005) as a search model. Refinement was carried out with REFMAC5
(Murshudov et al., 1997) using TLS (Winn et al., 2001). Ramachan-
dran plots generated from PROCHECK indicate that the model
exhibits good stereochemistry, with 100% of the residues in the
allowed regions. Structural superpositions were performed with SHP
(Stuart et al., 1979) and figures were drawn using PyMOL (DeLano,
2002).
3. Results and discussion
3.1. Overall structure of SaGMK
SaGMK crystallized with two dimers in the asymmetric unit. Each
monomer is bound through its P-loop to a sulfate ion (Fig. 1b).
Sulfate at 200 mM is a component of the crystallization medium and
competition with ATPS (5 mM) may account for the lack of binding
of this ATP analogue in the crystal. In turn, the absence of bound
ATP may explain why the lid domain is disordered and not observed
in our structure. The sulfate ion has been proposed to mimic the ATP
or ADP -phosphate (Hible et al., 2005). Indeed, the structure of
mouse GMK in a closed conformation (PDB code 1lvg) shows that
the P-loop interacts with an ADP -phosphate. The binding of the
sulfate ion to the P-loop may not be sufficient to fully order the lid
domain. Indeed, a sulfate ion has been observed in this position in
other NMPKs (Blaszczyk et al., 2001), yet does not lead to the
complete closure of the lid domain (Hible et al., 2005). Electron
density for GMP is clearly seen in only three of the four SaGMK
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Table 1
Statistics for crystallographic structure determination.
Values in parentheses are for the outermost resolution shell.
Data collection
Data-collection site ESRF ID14.1
Detector MAR CCD
Wavelength (A˚) 0.93
Resolution range (A˚) 30–1.9 (1.97–1.90)
Redundancy 3.6 (2.9)
Completeness (%) 99.3 (95.6)
Average I/(I) 31.6 (2.9)
Rmerge† 0.037 (0.275)
Refinement statistics
No. of reflections used 75428
Total No. of atoms 6201
No. of water molecules 471
Resolution range (A˚) 29.4-1.9
R factor‡ (Rwork/Rfree) 20.7/23.9
R.m.s. bond-length deviation (A˚) 0.013
R.m.s. bond-angle deviation () 1.32
Mean B factors (A˚2)
Main chain 23.2
Side chain and water 27.3
GMP 22.8
All atoms 25.6
† Rmerge =
P jI  hIij=PhIi. ‡ R factor =P jFo  Fcj=
P
Fo.
molecules; thus, the present structure allows study of the domain
movement triggered by the binding of GMP.
SaGMK forms a dimer which is similar to that reported in the
crystal structure of EcGMK (PDB code 1s96; Fig. 1b). The monomers
are related by a twofold axis perpendicular to the helices responsible
for the dimer stabilization. Surprisingly, in our structure the
crystallographic dimer is also linked by a disulfide bridge between
Cys182 of each monomer (Fig. 1b). As the cytoplasm is essentially a
reducing environment (Kadokura et al., 2003), this disulfide bridge is
unlikely to normally exist in vivo. Nevertheless, because the SaGMK
dimer is very similar to the EcGMK dimer, which does not have a
disulfide involved in stabilization, we can infer that this crystallo-
graphic dimer is biologically relevant. This is supported by dynamic
light-scattering studies showing the presence of a single species
corresponding to a dimer (Fig. 2). Nevertheless, it might also be
possible that under solution conditions different from ours, SaGMK
may form higher order oligomers as reported for EcGMK (Hible et
al., 2005). Additionally, it should be noted that structures of
M. tuberculosis GMKs have been reported with and without intra-
dimer disulfide bonds (Hible, Christova et al., 2006), but the differing
oxidation states do not apparently give rise to significant conforma-
tional changes.
As expected, the overall fold of SaGMK is very similar to those of
other GMKs (Figs. 1a and 3). The core domain (residues 4–33, 99–126
and 164–191) is a four-stranded -sheet flanked by four -helices. The
NMP-binding site (residues 39–91) consists of two -helices and four
-strands (Fig. 1a). The lid domain (residues 124–158) is disordered in
our structure. In EcGMK, the C-terminus is longer than in other
GMKs of known crystal structure and is mainly responsible for the
formation of dimers (Hible et al., 2005). In the SaGMK structure, the
C-terminus (residues 191–207) is of similar length to that of EcGMK,
suggesting that GMKs containing this C-terminal extension (such as
Salmonella typhimurium or Vibrio cholerae GMKs) are very likely to
form dimers or oligomers. Indeed, GMKs from M. tuberculosis,
S. cerevisiae and mouse have a shorter C-terminus and are known to
behave as monomeric enzymes.
3.2. Active-site structure
The SaGMK active site (Fig. 4b) is very similar to that of mouse
GMK, indicating that achieving drug selectivity towards a eukaryotic
GMK in this region may not be straightforward. Indeed, the main
interactions involved in GMP binding are the same as those
previously reported in the S. cerevisiae GMK structure. The guanine
ring makes hydrogen bonds to the conserved Glu74 and Ser39 and
also to Glu105. The latter is replaced by an aspartate (Asp103) in the
mouse GMK structure. The phosphate hydrogen bonds to Tyr55,
Tyr83 and Arg43. A second arginine (Arg46) stabilizes a water
molecule which is in contact with the GMP phosphate. The equivalent
arginine inM. tuberculosis GMK (Arg60) or in mouse GMK (Arg44)
hydrogen bonds to the GMP phosphate.
One interesting feature found in the active site is the presence of a
potassium ion close to the GMP guanine ring (Fig. 4b). This ion has
been reported in the mouse GMP structure at a similar position to
that observed here. The potassium ion is in contact with the guanine
ring N7 (3.1 A˚ compared with 2.8 A˚ in the mouse structure; PDB
code 1lgv). In the SaGMK and mouse GMK structures the potassium
ion is coordinated to the side chain of a serine (Ser39 and Ser37,
respectively), to the main-chain carbonyl of an acidic residue (Glu103
and Asp101, respectively) and to three water molecules. In the
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Figure 2
Representative DLS mass particle size distribution of SaGMK (1 mg ml1) in
20 mM Tris pH 7, 150 mM NaCl, 1 mM DTT. The protein displays a hydrodynamic
radius of 3.1 nm, which gives an extrapolated molecular weight of 47.5 kDa
corresponding to a dimer of SaGMK.
Figure 1
(a) Ribbon diagram and surface representation of SaGMK, showing the various
domains. The NMP domain is coloured yellow, the core domain green, the visible
part of the lid domain orange and the C-terminal domain raspberry. (b) Ribbon
diagram showing superimposition of the SaGMK and EcGMK dimers. Bound
ligands in SaGMK (GMP, sulfate) and the intradimer disulfide bridge are shown in
standard atom colours. SaGMK subunits are coloured blue and red, whilst the
EcGMK structure is coloured grey.
SaGMK structure there is an extra metal–ligand contact made
between the potassium ion and the Tyr36 side-chain O atom lone pair.
This latter contact is absent in mouse GMK since the tyrosine is
replaced by phenylalanine. The importance of the potassium for the
binding of GMP is not known. However, from our structure we can
infer that the presence of this ion is related to the binding of GMP as
no potassium is seen in the unliganded SaGMK. The potassium ion,
which comes from the enzyme-storage buffer and the crystallization
reservoir solution (40 mM KCl in each case), may play a role in GMP
binding by linking the nucleotide to a nearby residue.
3.3. Domain movements
The presence of liganded and unliganded SaGMK in the same
crystal allows the identification of conformational changes induced by
the binding of GMP (Figs. 4a and 4b). As expected, the binding of
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Figure 3
Amino-acid sequence alignment of human GMK, mouse GMK and SaGMK. SaGMK is 33 and 35% identical to human and mouse GMKs, respectively. Human and mouse
GMKs share 87% sequence identity.
Figure 4
(a) Ribbon diagram showing the superimposition of the SaGMK open state (coloured yellow), closed state (coloured raspberry) and the mouse GMK closed state (coloured
blue). The SaGMK ligands, sulfate and GMP, are in grey. (b) Stereo diagram showing the superimposition of the open conformation of the SaGMK active site (transparent
representation) onto the closed conformation. The GMP and sulfate are in standard atom colours; the potassium ion is coloured cyan.
GMP induced domain movements in SaGMK. The NMP-binding
domain and the P-loop moved towards each other, bringing GMP and
the sulfate ion into close proximity (Fig. 4a).
In the SaGMK active site (Fig. 4b), the essential residues for GMP
binding move to form a more compact pocket around the substrate.
Interestingly, the side chain of Glu105 is rotated by 180 about the
C—C bond in order to avoid a clash with the ribose ring. Tyr36 is
not in direct contact with GMP; rather, it interacts via the potassium
ion in the closed form. In the open form, the Tyr36 side chain points
approximately 90 away from this direction. Thus, it seems that the
potassium ion is responsible for the Tyr36 side-chain movement. It
would be interesting to study the effect of the potassium ion on the
enzyme reaction in order to determine if it is essential, at least for
mouse GMK and SaGMK. For example, if Tyr36 was mutated to
phenylalanine, the effects of the predicted loss in potassium binding
on catalytic turnover or GMP binding could be assessed. Such
information could be relevant for structure-based drug design
involving GMKs in a range of therapeutic areas. Thus, inhibitors
targeting SaGMK as potential antibacterials could be optimized for
potency. Additionally, it could provide the basis for the improvement
of compounds metabolized by mammalian GMKs; for example,
anticancer prodrugs which undergo activation, including thiopurines
(Sekulic et al., 2002).
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